** Sera Prognostics Inc's SERA.O shares down 15.3% premarket to $3.77, over 1-yr low, after overnight follow-on priced
** Salt Lake City-based women's health firm late Mon announced 12.5 mln shares, including 11.25 mln pre-funded warrants, at $4 for $50 mln gross proceeds
** Offering price is 10.1% discount to last sale
** Co intends to use net offering proceeds to expand commercial infrastructure in the U.S., accelerate preparations for expansion in the European Union, fund additional studies to increase adoption of its blood test to predict preterm birth risks, PreTRM, including a potential submission to U.S. FDA for broad approval
** Jefferies, TD Cowen and William Blair are jt bookrunners, along with RBC
** Co has ~33.77 mln shares outstanding for market cap of ~$150 mln and ~28.6 mln shares of free float, per LSEG
** SERA shares, which have fallen 6 of the past 7 sessions, have declined 45% YTD through Mon close
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.